Day: September 7, 2022

VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) — New Leaf Ventures Inc. (CSE: NLV) (OTC: NLVVF) (“New Leaf,” “NLV” or the “Company”), announces that the Company’s Board of Directors has determined to consolidate the Company’s issued share capital on a ratio of one (1) new post-consolidated common share for every five (5) old pre-consolidated common shares (the “Consolidation”). The Company currently has 62,770,115 issued and outstanding common shares and on completion of the Consolidation there is expected to be 12,554,023 issued and outstanding common shares. The Company’s name and trading symbol will remain the same. Shareholder approval of the Consolidation is neither required under the policies of the Canadian Securities Exchange (the “CSE”) nor under the Articles of the Company. The Board of...

VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) — Tactical Resources Corp. (CSE: RARE) (OTC: USREF) (“Tactical Resources” or the “Company”) announces that at the Company’s September 7, 2022 Annual General and Special Meeting (the “Meeting”), Shareholders of the Company approved new Business Corporations Act (British Columbia) Articles of the Company, to include advance notice relating to the nomination of individuals for election of directors. The advance notice provisions are designed to: (i) facilitate orderly and efficient shareholder meetings at which directors are to be elected; (ii) ensure that all shareholders, including those participating in a shareholders’ meeting by proxy rather than in person, receive adequate notice of all director nominations and sufficient information with respect to all nominees; and...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) announced today that it has renewed its at-the-market equity program (“ATM Program”) to allow the Company to issue up to an additional $750 million of common shares from treasury (the “Common Shares”) to the public from time to time, at the Company’s discretion in connection with the ATM Program. The ATM Program was renewed following the termination of the Company’s previous at-the-market equity program as a result of having sold most of the Common Shares permitted to be sold under the previous program. Any Common Shares sold in the ATM Program will be sold through the facilities of the Toronto Stock Exchange (the “TSX”) or any other marketplace...

TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that at August 31, 2022, its unaudited net asset value per share (“NAV”) was $0.93.   This announcement is made based on ThreeD’s established practice of releasing NAV on a monthly basis as part of the Company’s ongoing response to shareholder interest in receiving periodic information. NAV is calculated based on unaudited month-end financial information. Use of Non-GAAP Financial Measures: This press release contains references to NAV or “net asset value per share” which is a non-GAAP financial measure. NAV is calculated as the value of total assets less the...

ROMEOVILLE, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) — Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today filed an 8-K referencing that BASF, one of its customers, filed a complaint against Nanophase in the Superior Court of New Jersey. Among other things, the complaint alleges that Nanophase breached the exclusivity provisions of a supply agreement through the sale of zinc oxide based products through its Solésence subsidiary. In response to BASF’s action, Nanophase has in turn filed a Complaint for Declaratory Judgment in the Circuit Court of Cook County regarding the exclusivity terms within the agreement. While...

— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-breaking, proffered paper presentation at ESMO — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to discuss the full trial results and the unmet medical need in colorectal cancer — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces summary results of the 691-patient, multi-regional clinical trial (“MRCT”) of fruquintinib. These results have been shared in an abstract of the upcoming presentation at the European Society for Medical Oncology Congress...

TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Unigold Inc. (“Unigold” or the “Company”) (TSX-V:UGD, OTCQX:UGDIF, FSE:UGB1) is pleased to announce that it has closed a first tranche (“First Tranche”) of a non-brokered private placement of up to 20,000,000 units of the Company (each, a “Unit”) at a price of $0.08 per Unit for gross proceeds of up to $1,600,000 (the “Offering”). Each Unit consists of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of $0.30 until the date that is the earlier of: (i) one year following the date of issue, or (ii) 30 days after the date on which the Company...

Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to placebo Biogen is currently enrolling people with active SLE into two Phase 3 studies in 31 countries worldwide and plans to initiate a pivotal study in cutaneous lupus erythematosus (CLE) later this year Positive CLE results from Part B of LILAC were published separately in The New England Journal of Medicine, illustrating the body of evidence supporting the continued development of litifilimab for lupusCAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published a second manuscript detailing positive results from the company’s two-part...